445 related articles for article (PubMed ID: 24472251)
1. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy.
Hirota T; Schwartz S; Correll CU
J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):153-73. PubMed ID: 24472251
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
Schwartz S; Correll CU
J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):174-87. PubMed ID: 24472252
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
Pringsheim T; Hirsch L; Gardner D; Gorman DA
Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
[TBL] [Abstract][Full Text] [Related]
4. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
[TBL] [Abstract][Full Text] [Related]
5. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
McCracken JT; McGough JJ; Loo SK; Levitt J; Del'Homme M; Cowen J; Sturm A; Whelan F; Hellemann G; Sugar C; Bilder RM
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):657-666.e1. PubMed ID: 27453079
[TBL] [Abstract][Full Text] [Related]
6. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
Connor DF; Findling RL; Kollins SH; Sallee F; López FA; Lyne A; Tremblay G
CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
[TBL] [Abstract][Full Text] [Related]
7. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
Jain R; Segal S; Kollins SH; Khayrallah M
J Am Acad Child Adolesc Psychiatry; 2011 Feb; 50(2):171-9. PubMed ID: 21241954
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
Cerrillo-Urbina AJ; García-Hermoso A; Pardo-Guijarro MJ; Sánchez-López M; Santos-Gómez JL; Martínez-Vizcaíno V
J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):494-507. PubMed ID: 29897263
[TBL] [Abstract][Full Text] [Related]
9. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
Sallee F; Connor DF; Newcorn JH
J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.
Sallee FR; Kollins SH; Wigal TL
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):206-14. PubMed ID: 22612526
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
Bilder RM; Loo SK; McGough JJ; Whelan F; Hellemann G; Sugar C; Del'Homme M; Sturm A; Cowen J; Hanada G; McCracken JT
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):667-73. PubMed ID: 27453080
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
[TBL] [Abstract][Full Text] [Related]
13. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Cutler AJ; Brams M; Bukstein O; Mattingly G; McBurnett K; White C; Rubin J
J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
[TBL] [Abstract][Full Text] [Related]
14. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
15. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
Martinez-Raga J; Knecht C; Szerman N; Martinez MI
CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
[TBL] [Abstract][Full Text] [Related]
18. Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder.
Childress AC; Sallee FR
Drugs Today (Barc); 2012 Mar; 48(3):207-17. PubMed ID: 22462040
[TBL] [Abstract][Full Text] [Related]
19. Guanfacine extended-release: in attention deficit hyperactivity disorder.
Muir VJ; Perry CM
Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents.
Bello NT
Patient Prefer Adherence; 2015; 9():877-85. PubMed ID: 26170637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
